Medicine and Dentistry
Somatomedin C Receptor
100%
Breast Cancer
42%
Mammalian Target of Rapamycin
42%
Antibody
28%
Programmed Cell Death
28%
Combination Therapy
28%
Hormone Receptor
21%
Ligand
21%
Mitogen-Activated Protein Kinase
21%
Clinical Trial
21%
In Vitro
14%
Chemotherapeutic Agent
14%
Tumor Xenograft
14%
Necrosis
14%
Neoplasm
14%
Targeted Therapy
14%
Cancer Cell
14%
Monoclonal Antibody
7%
Cytotoxicity
7%
Cell Proliferation
7%
Inpatient
7%
Oncology
7%
Uvomorulin
7%
Tumor Cell
7%
Drug
7%
Breast
7%
Anticarcinogen
7%
Cell Migration
7%
Gamma Urogastrone
7%
Carcinogenesis
7%
Adjuvant Chemotherapy
7%
Cells
7%
Phosphorylation
7%
Patient
7%
Metastatic Carcinoma
7%
Epidermal Growth Factor Receptor
7%
Disease Free Survival
7%
Evaluation Study
7%
Cell Invasion
7%
Diseases
7%
Therapeutic Procedure
7%
Tamoxifen
7%
Introspection
7%
Hormone Therapy
7%
Relapse
7%
Trastuzumab
7%
Hyperactivation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Somatomedin C Receptor
100%
Breast Cancer
42%
Antibody
28%
Ligand
21%
Hormone Receptor
21%
Insulin-Like Growth Factor 1
14%
Neoplasm
14%
Necrosis
14%
Tamoxifen
7%
Mouse
7%
Uvomorulin
7%
Carcinogenesis
7%
Relapse
7%
Disease Free Survival
7%
Gamma Urogastrone
7%
Epidermal Growth Factor Receptor
7%
Anticarcinogen
7%
Trastuzumab
7%
Drug
7%
Monoclonal Antibody
7%
Diseases
7%
Rodent
7%
Metastasis
7%
Biochemistry, Genetics and Molecular Biology
Insulin-Like Growth Factor 1 Receptor
100%
Hormone Receptor
21%
Mitogen-Activated Protein Kinase
21%
Apoptosis
14%
Cancer Cell
14%
Cell Death
14%
Trastuzumab
7%
Cell Invasion
7%
Relapse
7%
Cell Migration
7%
Cell Proliferation
7%
Cytotoxicity
7%
Disease Free Survival
7%
Mouse
7%
Phosphorylation
7%
Cadherin
7%
Rodent
7%
Insulin-Like Growth Factor 1
7%
Epidermal Growth Factor Receptor
7%
Introspection
7%
Tumor Volume
7%
Monoclonal Antibody
7%